@article{1e2dd4391a9643dfbfde5ea1f248b48a,
title = "End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET",
author = "Chohan, {Karan L.} and Young, {Jason R.} and Scott Lester and Moustafa, {Muhamad Alhaj} and Allison Rosenthal and Tun, {Han W.} and Hoppe, {Bradford S.} and Johnston, {Patrick B.} and Micallef, {Ivana N.} and Habermann, {Thomas M.} and Ansell, {Stephen M.}",
note = "Funding Information: HWT serves in a consulting/advisory role for Acrotech, Gossamerbio, and ADC Therapeutics, and receives research funding from Acrotech. TMH serves on scientific advisory boards for Eli Lilly & Co., Morphosys, Incyte, Biegene, and Loxo Oncology, has received research funding from Genentech, and serves on the data monitoring committee for Seagen, and Tess Therapeutics. SMA receives research funding from Bristol-Myers Squibb, Seattle Genetics, Affimed Therapeutics, Regeneron, Trillium Therapeutics, AI Therapeutics, and ADC Therapeutics. KLC, JRY, SL, MAM, AR, BSH, PBJ, and INM, have no conflicts of interest to disclose.",
year = "2023",
month = jun,
doi = "10.3324/haematol.2022.282115",
language = "English (US)",
volume = "108",
pages = "1697--1701",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "6",
}